Carhart-HarrisRGiribaldiBWattsR, et al. (2021a) Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine384(15): 1402–1411.
2.
Carhart-HarrisRLBruggerSNuttDJ, et al. (2013) Psychiatry’s next top model: Cause for a re-think on drug models of psychosis and other psychiatric disorders. Journal of Psychopharmacology27(9): 771–778.
3.
Carhart-HarrisRLWagnerACAgrawalM, et al. (2021b) Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?Journal of Psychopharmacology. Epub ahead of print 22April. DOI: 10.1177/02698811211008567.
4.
CleareAParianteCMYoungAH, et al. (2015) Members of the consensus meeting: Evidence-based guidelines for treating depressive disorders with antidepressants – A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology29(5): 459–525.
5.
ConleyAANorwoodAEQHatvanyTC, et al. (2021) Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology238(7): 1737–1752.
6.
DawsonGRDourishCTGoodwinGM (2011) Special issue on CNS experimental medicine. Journal of Psychopharmacology25(9): 1145–1147.
7.
DiamondPRFarmeryADAtkinsonS, et al. (2014) Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic. Journal of Psychopharmacology28(6): 536–544.
8.
Dos SantosRGHallakJEBakerG, et al. (2021) Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Journal of Psychopharmacology35(4): 453–458.
9.
FinebergNAHaddadPMCarpenterL, et al. (2013) The size, burden and cost of disorders of the brain in the UK. Journal of Psychopharmacology27(9): 761–770.
10.
GordonJA (2019) From neurobiology to novel medications: A principled approach to translation. American Journal of Psychiatry176(6): 425–427.
11.
IllingworthBJLewisDJLambarthAT, et al. (2021) A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. J Psychopharmacol35(5): 501–511.
12.
JauharSHayesJGoodwinGM, et al. (2019) Antidepressants, withdrawal, and addiction; where are we now?Journal of Psychopharmacology33(6): 655–659.
13.
JelenLAYoungAHStoneJM (2021) Ketamine: A tale of two enantiomers. Journal of Psychopharmacology35(2): 109–123.
14.
JonesGNockM (2022a) Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Journal of Psychopharmacology36(1): 57–65.
15.
JonesGNockM (2022b) MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of U.S. adults. Journal of Psychopharmacology36(1): 46–56.
16.
JonesGNockM (2022c) Psilocybin use is associated with lowered odds of crime arrests in U.S. adults: A replication and extension. Journal of Psychopharmacology36(1): 66–73.
17.
KuypersKPNgLErritzoeD, et al. (2019) Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology33(9): 1039–1057.
18.
LegerRFUnterwaldEM (2022) Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Journal of Psychopharmacology. Epub ahead of print 14September. DOI: 10.1177/02698811211044688.
19.
McCullochDEMadsenMKStenbækDS, et al. (2022) Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. Journal of Psychopharmacology. Epub ahead of print 30June. DOI: 10.1177/02698811211026454.
20.
MarschallJFejerGLempeP, et al. (2022) Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. Journal of Psychopharmacology36(1): 96–112.
21.
NuttDJGoodwinGMBhugraD, et al. (2014) Attacks on antidepressants: Signs of deep-seated stigma?The Lancet Psychiatry1(2): 102–104.
22.
PeillJTrinciKKettnerH, et al. (2022) Validation of the psychological insight scale; a new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology36(1): 31–45.
23.
PetrankerRAndersonTMaierLJ, et al. (2022) Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. Journal of Psychopharmacology. Epub ahead of print 8October. DOI: 10.1177/0269881120953994.
24.
RuckerJJYoungAH (2021) Psilocybin: From serendipity to credibility?Frontiers in Psychiatry12: 659044.
25.
RuckerJJMarwoodLAjantaivalR-LJ, et al. (2022) The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Journal of Psychopharmacology36(1): 119–130.
26.
SumnerRLChackoEMcMillanR, et al. (2021) A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties. Journal of Psychopharmacology35(8): 946–961.
27.
TeixeiraPJJohnsonMWTimmermannC, et al. (2022) Psychedelics and health behaviour change. Journal of Psychopharmacology. Epub ahead of print 29May. DOI: 10.1177/02698811211008554.
28.
YoungAHMoultonCD (2020) Antidepressants do work after all. Journal of Psychopharmacology34(10): 1071–1073.
